Blaine H. McKee, PhD
Blaine McKee has served as member of our Board of Directors since March 10, 2016. He is a broadly skilled senior executive with over 20 years leadership experience in global biotechnology business development. Dr. McKee joined Shire in 2014 to lead its business development function. He was previously EVP and Chief Business Officer at 480 Biomedical, following 15 years at Genzyme Corporation, where he served as SVP of Strategic Development, leading global business development for the Organ Transplant, Oncology and Multiple Sclerosis business units. Dr. McKee contributed materially to the transformation of the oncology business at Genzyme from an early-stage research operation to a competitive and sustainable oncology and solid organ transplantation franchise, with global revenues of approximately $700M in 2011. Dr. McKee is also on the boards of ArmaGen, OrbiMed Israel, and the New York Pharma Forum. He received his Bachelor of Science degree from Colorado State University, his PhD from the Massachusetts Institute of Technology, and his MBA from the MIT Sloan School of Management.